Democratic People's Republic of KoreaTuberculosis profile
Population  2015 25 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 15 (10–22) 61 (40–87)
Mortality (HIV+TB only) 0.037 (0.016–0.065) 0.15 (0.07–0.26)
Incidence  (includes HIV+TB) 141 (109–178) 561 (432–706)
Incidence (HIV+TB only) 0.45 (0.32–0.6) 1.8 (1.3–2.4)
Incidence (MDR/RR-TB)** 6 (3.4–8.6) 24 (14–34)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 4.9 (2–7.8) 49 (30–69) 54 (32–76)
Males 6 (3.7–8.3) 81 (61–101) 87 (65–109)
Total 11 (7.4–14) 130 (111–149) 141 (109–178)
TB case notifications, 2015  
Total cases notified 120 722
Total new and relapse 112 840
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 0%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 50%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.07–0.17)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 0  
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  4 600
(2 600–6 500)
Estimated % of TB cases with MDR/RR-TB 2.2% (0.51–3.9) 16% (8.4–24)  
% notified tested for rifampicin resistance 0% 2% 336
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 209, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 125, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 91% 103 045
Previously treated cases, excluding relapse, registered in 2014 82% 7 245
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013 84% 170
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 30
Funding source: 19% domestic, 27% international, 54% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data